Stockreport

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

Kymera Therapeutics, Inc. (KYMR)

More Company Research Source: GlobeNewswire

PDF KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data ex [Read more]

EVENT DAY Stock performance from the time of news release until the following 4pm ET market close	LAST PRICE AT NEWS EVENT {{SecondSection.LastPriceAtNewsEvent}}	SINCE EVENT Multi-day stock performance from the time of the news release
{{FirstSection.LastPrice}}	LAST PRICE	{{SecondSection.LastPrice}}
{{FirstSection.VWapStr_AMP}} {{FirstSection.VwapEventTime}}	VWAP	{{SecondSection.VWapStr_AMP}} {{SecondSection.VwapEventTime}}
{{FirstSection.MaxUp}} High: {{FirstSection.EodHigh}}	MAX UP	{{SecondSection.MaxUp}} High: {{SecondSection.EodHigh}}
{{FirstSection.MaxDown}} Low: {{FirstSection.EodLow}}	MAX DOWN	{{SecondSection.MaxDown}} Low: {{SecondSection.EodLow}}
{{FirstSection.TodaysRangeStr_AMP}} {{FirstSection.RangEvg}}	POST NEWS RANGE	{{SecondSection.TodaysRangeStr_AMP}} {{SecondSection.RangEvg}}
{{FirstSection.PriceChange}} {{FirstSection.PriceChangeTriangle_AMP}}	PRICE CHANGE	{{SecondSection.PriceChange}} {{SecondSection.PriceChangeTriangle_AMP}}
{{FirstSection.PriceChangePercent}}	PRICE CHANGE PERCENTAGE	{{SecondSection.PriceChangePercent}}
{{FirstSection.Spx500}}	S&P 500 (SPX)	{{SecondSection.Spx500}}
{{FirstSection.VolumeImpactStr_AMP}}	VOLUME RATIO	{{SecondSection.VolumeImpactStr_AMP}}
{{FirstSection.Volume}}	VOLUME (SHARES)	{{SecondSection.Volume}}
{{FirstSection.TicksString}}	TICKS	{{SecondSection.TicksString}}
{{FirstSection.AvgTransactionSizeStr_AMP}}	AVG SHARES PER TRADE	{{SecondSection.AvgTransactionSizeStr_AMP}}

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

{{GreenBoxData.Blurb}}

Opt in for alerts from News Quantifed